Antiretroviral treatment and advanced age: Epidemiologic, laboratory, and clinical features in the elderly [1]

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 1, 2003, Pages 112-114

  Manfredi, Roberto ^a   Calza, Leonardo ^a   Cocchi, Davide ^a   Chiodo, Francesco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ADULT; AGE; AGED; COGNITION; COMORBIDITY; CONTROLLED STUDY; DEATH; DISEASE COURSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GERIATRIC DISORDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; T LYMPHOCYTE SUBPOPULATION; TIME SERIES ANALYSIS; VIREMIA;

EID: 0038372692     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200305010-00016     Document Type: Letter

References (17)

1. Manfredi R, Chiodo F. A case-control study of virological and immunological effects of highly active antiretroviral therapy in HIV-infected patients with advanced age. AIDS. 2000;14:1475-1477.
2. NAHOF Connection. Newsletter of the National Association of HIV over fifty. 2002. Available at: http://www.hivoverfifty.org.
3. Chaisson RE, Keruly JC, Moore RD, et al. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med. 1995;333:751-756.
4. Keller MJ, Hausdorff JM, Kyne L, et al. Is age a negative prognostic indicator in HIV infection of AIDS? Aging. 1999;11:35-38.
5. Linsk NL. HIV among older adults: age specific issues in prevention and management. AIDS Reader. 2000;10:430-440.
6. Shah SS, McGowan JP, Smith C, et al. Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City. Clin Infect Dis. 2002;35:1238-1243.
7. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature. 1998;396:690-695.
8. Smith KY, Valdez H, Landay A, et al. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. J Infect Dis. 2000;181:141-147.
9. Manfredi R, Calza L, Chiodo F. Functional and morphologic features of thymic response during antiretroviral therapy [abstract]. In Abstracts of the Sixth International Congress on Drug Therapy in HIV Infection, Glasgow, November 2002.
10. Emlet CA, Farkas KJ. Correlates of service utilization among midlife and older adults with HIV/AIDS: the role of age in equation. J Aging Health. 2002;14:315-335.
11. Hinkin CH, Castellon SA, Durvasula RS, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology. 2002;59:1944-1950.
12. Manfredi R. Evolution of HIV disease in the third millennium: clinical and related economic issues. Int J Antimicrob Agents. 2002;19:251-253.
13. Manfredi R. HIV disease and advanced age: an increasing therapeutic challenge. Drugs Aging. 2002;19:647-669.
14. Dufour A, Alary M, Otis J, et al. Correlates of risky behaviors among young and older men in Montreal, Quebec, Canada. J Acquir Immune Defic Syndr. 2000;23:272-278.
15. Tan HH, Chan RK, Goh CL. Sexually transmitted diseases in the older population in Singapore. Ann Acad Med Singapore. 2002; 31:493-496.
16. Pakker NG, Kroon EDMB, Roos MTL, et al. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. AIDS. 1999;13:203-212.
17. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000;30(Suppl 1):S29-65.